Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ACPGFNASDAQ:ATNFWOTCMKTS:EAHGFOTCMKTS:MKGAY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACPGFAcacia Pharma Group$0.99$0.99$0.76▼$4.00N/AN/A4,104 shsN/AATNFW180 Life Sciences$0.01-4.7%$0.01$0.00▼$0.04N/AN/A96,127 shs971 shsEAHGFECO Animal Health Group$2.00$2.00$2.00▼$2.00N/AN/A2,550 shsN/AMKGAYMerck KGaA$38.36$38.36$32.53▼$42.02N/AN/A6,872 shsN/ABeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACPGFAcacia Pharma Group0.00%0.00%0.00%0.00%0.00%ATNFW180 Life Sciences+7.50%+3.61%+7.50%+22.86%-14.00%EAHGFECO Animal Health Group0.00%0.00%0.00%0.00%0.00%MKGAYMerck KGaA0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACPGFAcacia Pharma GroupN/AN/AN/AN/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AEAHGFECO Animal Health GroupN/AN/AN/AN/AN/AN/AN/AN/AMKGAYMerck KGaAN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACPGFAcacia Pharma Group 0.00N/AN/AN/AATNFW180 Life Sciences 0.00N/AN/AN/AEAHGFECO Animal Health Group 0.00N/AN/AN/AMKGAYMerck KGaA 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACPGFAcacia Pharma GroupN/AN/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/AN/AN/AN/AN/AEAHGFECO Animal Health GroupN/AN/AN/AN/AN/AN/AMKGAYMerck KGaAN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACPGFAcacia Pharma GroupN/AN/A0.00∞N/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/A0.00∞N/AN/AN/AN/AN/AEAHGFECO Animal Health GroupN/AN/A0.00∞N/AN/AN/AN/AN/AMKGAYMerck KGaAN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACPGFAcacia Pharma GroupN/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/AN/AN/AN/AEAHGFECO Animal Health GroupN/AN/AN/AN/AN/AMKGAYMerck KGaAN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACPGFAcacia Pharma GroupN/AATNFW180 Life SciencesN/AEAHGFECO Animal Health GroupN/AMKGAYMerck KGaAN/AInsider OwnershipCompanyInsider OwnershipACPGFAcacia Pharma GroupN/AATNFW180 Life SciencesN/AEAHGFECO Animal Health GroupN/AMKGAYMerck KGaAN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACPGFAcacia Pharma Group72N/AN/ANot OptionableATNFW180 Life Sciences7N/AN/ANot OptionableEAHGFECO Animal Health Group207N/AN/ANot OptionableMKGAYMerck KGaAN/AN/AN/ANot OptionableMKGAY, ACPGF, EAHGF, and ATNFW HeadlinesRecent News About These CompaniesMerck KGaA shares phase 3 rare tumor data ahead of showdown with Daiichi and OnoMay 28, 2025 | fiercebiotech.comFMerck KGaA confirms late-stage talks with SpringWorks about $3.5B buyoutApril 25, 2025 | fiercepharma.comFMerck bets $200M on a new type of heart pillMarch 27, 2025 | biopharmadive.comBIs Merck Stock a Bargain Buy?March 27, 2025 | msn.comMerck KGaA reports YE24 earnings growth amid SpringWorks acquisition talksMarch 7, 2025 | msn.comSpringWorks cancelled from conference this week, says BarclaysMarch 6, 2025 | markets.businessinsider.comMerck KGaA says ‘no certainty’ SpringWorks deal will be signedMarch 6, 2025 | markets.businessinsider.comMerck KGaA Forecasts Earnings, Sales Growth After In-Line ResultsMarch 6, 2025 | marketwatch.comYAP-TEAD and TAZ-TEAD inhibitors revealed in Merck KGaA patentFebruary 27, 2025 | bioworld.comBMerck KGaA to replace two executives with company veteransFebruary 18, 2025 | msn.comMerck KGaA Appoints Three New Members to Executive BoardFebruary 18, 2025 | marketwatch.comWedbush ups SpringWorks target to $81, expects Merck KGaA ‘official’ offer soonFebruary 12, 2025 | markets.businessinsider.comSpringWorks shares up 39% to $55.90 after Merck KGaA confirms talksFebruary 11, 2025 | markets.businessinsider.comMerck KGaA in Talks to Buy SpringWorks TherapeuticsFebruary 10, 2025 | bloomberg.comExclusive-Germany's Merck KGaA in talks to buy US biotech firm Springworks, sources sayFebruary 10, 2025 | msn.comMerck 4Q Sales Increase Results in Swing to ProfitFebruary 4, 2025 | marketwatch.comMerck 4Q Earnings Rise; 2025 Outlook Hits Shares -- UpdateFebruary 4, 2025 | msn.comMerck Stock Tumbles on Weak Guidance and Gardasil Sales SlumpFebruary 4, 2025 | msn.comGuggenheim cuts Merck stock target, retains Buy on revised estimatesJanuary 17, 2025 | msn.comMerck, facing threat to Keytruda, buys into new kind of cancer immunotherapyNovember 14, 2024 | biopharmadive.comBMedia Sentiment Over TimeMKGAY, ACPGF, EAHGF, and ATNFW Company DescriptionsAcacia Pharma Group OTCMKTS:ACPGF$0.99 0.00 (0.00%) As of 06/16/2022Acacia Pharma Group plc discovers, develops, and commercializes pharmaceutical products for the patients undergoing surgery, invasive procedures, or chemotherapy treatments in the United States and internationally. The company's lead product is BARHEMSYS, an intravenous amisulpride for the treatment and prophylaxis of post-operative nausea and vomiting. Its products also include BYFAVO, an intravenous remimazolam and reversible IV sedative designed for use during invasive medical procedures, such as colonoscopy and bronchoscopy; and APD403, a selective dopamine antagonist amisulpride that has completed Phase II clinical trials for the treatment of chemotherapy-induced nausea and vomiting. Acacia Pharma Group plc was founded in 2007 and is based in Cambridge, the United Kingdom.180 Life Sciences NASDAQ:ATNFW$0.0082 0.00 (-4.65%) As of 12:34 PM Eastern180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.ECO Animal Health Group OTCMKTS:EAHGF$2.00 0.00 (0.00%) As of 12/28/2022ECO Animal Health Group plc, together with its subsidiaries, develops, registers, and markets pharmaceutical products for animals worldwide. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites, such as worms, ticks, mange, and lices in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline and Oxytetracycline for treatment of bacterial infections in pigs, poultry, and cattle. The company was founded in 1972 and is headquartered in New Malden, the United Kingdom.Merck KGaA OTCMKTS:MKGAY$38.36 0.00 (0.00%) As of 08/1/2017Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate and Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility. The Life Science sector provides scientists with laboratory materials, technologies, and services. The Performance Materials sector offers specialty chemicals and materials for demanding applications. The firm offers pharma and biopharma manufacturing, pharmaceutical research, pharma quality control, and government and academic research services. The company was founded by Friedrich Jacob Merck in 1668 and is headquartered in Darmstadt, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Jefferies Raises Broadcom Price Target to $315: 19% Upside Ahead Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock 3 Utility Stocks That Combine Income and Stability 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
